Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr Gill on a Survey of Patient Experiences and Involvement in Decision-Making in CRC

September 19th 2025

Sharlene Gill, BScPharm, MD, MPH, MBA, FRCPC, discusses patient experiences and involvement in decision-making in CRC.

FDA Approves Subcutaneous Pembrolizumab for Solid Tumors

September 19th 2025

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Dr Bekaii-Saab on Evolving Sequencing Approaches in CRC

September 18th 2025

Tanios S. Bekaii-Saab, MD, discusses sequencing decisions according to molecular subgroups in colorectal cancer.

New AACR Cancer Progress Report Spotlights Notable Gains, Ongoing Challenges in Research

September 17th 2025

AACR published its annual Cancer Progress Report, outlining advances in cancer treatment and areas for future improvement.

FDA Grants Premarket Approval to Idylla CDx MSI Test for MSI-H CRC

September 15th 2025

The Idylla CDx MSI Test will soon be available as a companion diagnostic for identifying patients with MSI-H CRC eligible for treatment with nivolumab.

Five Under 5: Top Oncology Videos for the Week of 9/7

September 14th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

Shield Blood Test Yields High Sensitivity, Specificity for CRC Screening in Expansion Cohort of Average-Risk Adults

September 12th 2025

The Shield blood-based CRC screening test demonstrated a sensitivity of 84% for detecting CRC with 90% specificity in an expanded cohort.

Dr Gill on the Rationale for Surveying Patients With mCRC About Treatment Decision-Making

September 8th 2025

Sharlene Gill, BScPharm, MD, MPH, MBA, FRCPC, discusses the rationale for evaluating patient experiences and involvement in CRC treatment decision-making.

Five Under 5: Top Oncology Videos for the Week of 8/31

September 7th 2025

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

The OncFive: Top Oncology Articles for the Week of 8/31

September 6th 2025

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Dr Eng on the Implications of a Real-World Study in KRAS G12C–Mutated CRC

September 5th 2025

Cathy Eng, MD, FACP, FASCO, discusses the clinical significance of a real-world study of KRAS G12C mutations on treatment outcomes in mCRC.

EU Approves MMR IHC Panel pharmDx as a Companion Diagnostic for Nivolumab/Ipilimumab in MSI-H/dMMR CRC

September 3rd 2025

The MMR IHC Panel pharmDx was certified in the EU as a companion diagnostic to identify patients with colorectal cancer eligible for nivolumab/ipilimumab.

Dr Wong on Next Steps for Validating the Predictive Utility of Molecular Characteristics in CRC

September 2nd 2025

Evelyn Y.T. Wong, MD, discusses discussed the potential use of molecular characteristics to predict survival outcomes in early-onset CRC.

Dr Schlechter on the Potential Future Implications of Botensilimab and Balstilimab in MSS mCRC

September 2nd 2025

Benjamin L. Schlecter, MD, discusses the potential next steps in research for botensilimab for the treatment of patients with metastatic colorectal cancer.

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

FDA Grants Breakthrough Device Designation to Haystack MRD ctDNA Liquid Biopsy for Stage II CRC

August 31st 2025

The FDA granted breakthrough device designation to the Haystack MRD ctDNA liquid biopsy for stage II colorectal cancer.

D3S-001 Receives FDA Breakthrough Therapy, Orphan Drug Designations in Select KRAS G12C-Mutant Solid Tumors

August 28th 2025

D3S-001 has received FDA breakthrough therapy and orphan drug designations in KRAS G12C-mutated NSCLC and CRC, respectively.

Five Under 5: Top Oncology Videos for the Week of 8/17

August 24th 2025

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

The OncFive: Top Oncology Articles for the Week of 8/17

August 23rd 2025

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

Dr Lai on Post-Induction Treatment Strategies in mCRC

August 22nd 2025

Connie Lai, MD, discusses an analysis of post-induction maintenance vs treatment break in metastatic colorectal cancer.